Trial
NCT00496756
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Nebraska
Collaborators
National Cancer Institute (NCI); Bayer
Condition
Kidney Cancer
Intervention
Sorafenib
Why stopped
Low accrual rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-26